{"id":"NCT02978326","sponsor":"Biogen","briefTitle":"A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression","officialTitle":"A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of SAGE-217 in the Treatment of Adult Female Subjects With Severe Postpartum Depression","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-01-04","primaryCompletion":"2018-11-15","completion":"2018-12-11","firstPosted":"2016-11-30","resultsPosted":"2021-12-16","lastUpdate":"2023-12-15"},"enrollment":276,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Postpartum Depression"],"interventions":[{"type":"DRUG","name":"SAGE-217 15/20 mg Oral Solution","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"SAGE 217 30 mg Capsules","otherNames":[]}],"arms":[{"label":"Part A: SAGE-217 15/20 mg Oral Solution","type":"EXPERIMENTAL"},{"label":"Part B: Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Part B: SAGE 217 30 mg Capsules","type":"EXPERIMENTAL"}],"summary":"The primary purpose of this study was to determine if treatment with SAGE-217 reduces depressive symptoms in participants with severe postpartum depression (PPD) compared to placebo as assessed by the change from baseline in the 17-item Hamilton Rating Scale for Depression (HAM-D) total score at Day 15 and to evaluate the safety and tolerability of SAGE-217 compared to placebo as assessed by the incidence of adverse events, vital sign measurements, clinical laboratory evaluations, electrocardiogram (ECG) parameters, and the Columbia Suicide Severity Rating Scale (C-SSRS).","primaryOutcome":{"measure":"Parts A and B: Change From Baseline in the 17-Item Hamilton Rating Scale for Depression (HAM-D) Total Score at Day 15","timeFrame":"Parts A and B: Baseline, Day 15","effectByArm":[{"arm":"Part B: Placebo","deltaMin":-13.6,"sd":1.07},{"arm":"Part B: SAGE 217 30 mg Capsules","deltaMin":-17.8,"sd":1.04}],"pValues":[{"comp":"OG001 vs OG002","p":"0.0028"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":27,"countries":["United States"]},"refs":{"pmids":["34190962","36724109"],"seeAlso":["http://www.sagerx.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":1},"commonTop":["Somnolence","Headache","Dizziness","Nausea","Upper respiratory tract infection"]}}